Published in Vaccine Weekly, September 6th, 2006
According to recent research from Austria, "The disialoganglioside GD2, a carbohydrate antigen, is expressed on all tumors of neuro-ectodermal origin, including melanoma, neuroblastoma, sarcoma, and small cell lung cancer. Due to its specific expression on tumor surfaces, GD2 is an attractive target for immunotherapies. The mouse/human chimeric anti-GD2 mAb ch14.18 is already applied in melanoma and neuroblastoma trials as a passive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly